AlphaStocks

CYTK vs HRMY

As of Sep 20, 2026, Cytokinetics (CYTK) scores 3.9/10 and Harmony Biosciences Holdings (HRMY) 7.5/10 on AlphaStocks' five-model composite, so HRMY scores higher.

CYTK

CYTOKINETICS INC

3.9

Weak

$68.74

HRMY

Harmony Biosciences Holdings, Inc.

7.5

Strong Buy

$42.06

CYTK vs HRMY: Which is the Better Investment?

CYTOKINETICS INC (CYTK) scores 3.9/10 while Harmony Biosciences Holdings, Inc. (HRMY) scores 7.5/10 on AlphaStocks' composite model. Harmony Biosciences Holdings, Inc. has the higher composite rating of Strong Buy.

This comparison is algorithmically generated and is not financial advice.

MetricCYTKHRMY
Scores & Fundamentals
Composite Score3.9/107.5/10
RatingWeakStrong Buy
Price$68.74$42.06
P/E Ratio15.5
ROE23.1%18.6%
Market Cap$8B$2B
Fair Value
Dividend Yield
Sector Rank#138 of 168#5 of 168
Model Verdicts
PiotroskiCautionAttractive
BuffettCautionAttractive
GrahamNeutralNeutral
LynchLimited DataStrong
GreenblattCautionStrong
View full CYTKanalysis →View full HRMYanalysis →

Related comparisons

Compare any two stocks →

CYTK vs HRMY: Which Stock Scores Higher?

CYTOKINETICS INC (CYTK) and Harmony Biosciences Holdings, Inc. (HRMY) are both in the Health Care sector. HRMY currently leads with a composite score of 7.5/10 (Strong Buy) compared to CYTK's 3.9/10 (Weak).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer